Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 61.96% is in line with its 5-year average of 64.79%, around the middle of its 5-year range (-8.21%–115.10%).
91.22% above its 12-month average of 32.40%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): -8.21%.
GROSS MARGIN
61.96%
GROSS MARGIN AVG TTM
32.40%
GROSS MARGIN AVG 3Y
52.93%
GROSS MARGIN AVG 5Y
64.79%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+91.22%
CURRENT VS 3Y AVG
+17.07%
CURRENT VS 5Y AVG
-4.37%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
39.94%
median of 722 covered companies
CURRENT VS SECTOR MEDIAN
+55.13%
vs the sector median at left
Market Cap
$6.43M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$6.49M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$5.98M
Gross Margin
100.00%
TTM Avg
100.00%
3Y Avg
100.00%
5Y Avg
83.33%
Market Cap
$6.74M
Gross Margin
-291.27%
TTM Avg
-237.54%
3Y Avg
-120.88%
5Y Avg
-89.07%
Market Cap
$6.66M
Gross Margin
64.28%
TTM Avg
69.38%
3Y Avg
65.33%
5Y Avg
71.21%
Market Cap
$5.93M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
-2.09%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Femasys Inc. (FEMY) | $6.24M | 61.96% | 32.40% | 52.93% | 64.79% |
| Biomerica, Inc. (BMRA)vs › | $6.40M | 8.09% | 8.76% | 9.29% | 9.67% |
| Ensysce Biosciences, Inc. (ENSC)vs › | $6.43M | 0.00% | 0.00% | 0.00% | 0.00% |
| Enveric Biosciences, Inc. (ENVB)vs › | $6.49M | 0.00% | 0.00% | 0.00% | 0.00% |
| Cardio Diagnostics Holdings, Inc. (CDIO)vs › | $5.98M | 100.00% | 100.00% | 100.00% | 83.33% |
| Aclarion, Inc. (ACON)vs › | $6.74M | -291.27% | -237.54% | -120.88% | -89.07% |
| Co-Diagnostics, Inc. (CODX)vs › | $6.66M | 64.28% | 69.38% | 65.33% | 71.21% |
| Enlivex Therapeutics Ltd. (ENLV)vs › | $5.93M | 0.00% | 0.00% | 0.00% | -2.09% |
| Lucyd, Inc (LUCY)vs › | $5.85M | 22.79% | 17.23% | 3.90% | 1.13% |
| Acurx Pharmaceuticals, Inc. (ACXP)vs › | $5.72M | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
62.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | -8.21% |
| 2026-03-31 | 15.49% |
| 2025-12-31 | 115.10% |
| 2025-09-30 | 30.78% |
| 2025-06-30 | 8.85% |
| 2025-03-31 | 65.64% |
| 2024-12-31 | 66.92% |
| 2024-09-30 | 65.61% |
| 2024-06-30 | 66.98% |
| 2024-03-31 | 67.35% |
| 2023-12-31 | 63.26% |
| 2023-09-30 | 64.73% |
| 2023-06-30 | 65.53% |
| 2023-03-31 | 64.24% |
| 2022-12-31 | 63.52% |
| 2022-09-30 | 62.17% |
| 2022-06-30 | 66.23% |
| 2022-03-31 | 61.83% |
| 2021-12-31 | 74.71% |
| 2021-09-30 | 60.90% |
| 2021-06-30 | 66.99% |
| 2021-03-31 | 71.79% |
| 2020-12-31 | 68.81% |
| 2020-09-30 | 71.13% |
| 2020-06-30 | 69.83% |
| 2020-03-31 | 71.91% |
